{
    "id": 3071,
    "name": "gliosarcoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3071",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00602667",
            "title": "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2449,
                    "therapyName": "Cisplatin + Cyclophosphamide + Methotrexate + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2450,
                    "therapyName": "Cyclophosphamide + Etoposide + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 2451,
                    "therapyName": "Cyclophosphamide + Erlotinib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00669669",
            "title": "Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2556,
                    "therapyName": "O6-benzylguanine",
                    "synonyms": null
                },
                {
                    "id": 2555,
                    "therapyName": "Carmustine + Filgrastim + Plerixafor + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00998010",
            "title": "Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3055,
                    "therapyName": "Bortezomib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01130077",
            "title": "A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01149850",
            "title": "Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01260506",
            "title": "Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2277,
                    "therapyName": "Bevacizumab + VB-111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01266031",
            "title": "Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2110,
                    "therapyName": "Bevacizumab + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01339039",
            "title": "Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2120,
                    "therapyName": "Bevacizumab + Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01421524",
            "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2358,
                    "therapyName": "CC-122",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01430351",
            "title": "Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8578,
                    "therapyName": "Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8577,
                    "therapyName": "Mefloquine + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8580,
                    "therapyName": "Memantine + Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8579,
                    "therapyName": "Mefloquine + Memantine + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8582,
                    "therapyName": "Mefloquine + Memantine + Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8581,
                    "therapyName": "Mefloquine + Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8576,
                    "therapyName": "Memantine + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01434602",
            "title": "Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2299,
                    "therapyName": "Everolimus + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01435395",
            "title": "Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2122,
                    "therapyName": "Bevacizumab + Bortezomib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01591577",
            "title": "Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2440,
                    "therapyName": "Lapatinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01721577",
            "title": "Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2745,
                    "therapyName": "AXL1717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730950",
            "title": "Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01753713",
            "title": "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01790503",
            "title": "A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 874,
                    "therapyName": "Pexidartinib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01837862",
            "title": "A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2134,
                    "therapyName": "Carboplatin + Mebendazole + Temozolomide + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2133,
                    "therapyName": "Bevacizumab + Irinotecan + Mebendazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01894061",
            "title": "NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01903330",
            "title": "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01931098",
            "title": "Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1469,
                    "therapyName": "Pazopanib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01977677",
            "title": "Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989052",
            "title": "Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 999,
                    "therapyName": "Carboxyamidotriazole Orotate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02052648",
            "title": "Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 2976,
                    "therapyName": "Indoximod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02078648",
            "title": "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3010,
                    "therapyName": "SL-701",
                    "synonyms": null
                },
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101905",
            "title": "Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02133183",
            "title": "TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02137759",
            "title": "MRSI to Predict Response to RT/TMZ and Vorinostat in GBM",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02152982",
            "title": "Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02197169",
            "title": "DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4407,
                    "therapyName": "DNX-2401",
                    "synonyms": null
                },
                {
                    "id": 4444,
                    "therapyName": "DNX-2401 + interferon gamma",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02238496",
            "title": "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2194,
                    "therapyName": "Perifosine + Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02311920",
            "title": "Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02337491",
            "title": "Pembrolizumab +/- Bevacizumab for Recurrent GBM",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2119,
                    "therapyName": "Bevacizumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02340156",
            "title": "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2518,
                    "therapyName": "SGT-53",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02386826",
            "title": "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2600,
                    "therapyName": "Bevacizumab + Capmatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02521090",
            "title": "EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1012,
                    "therapyName": "EGFRBi-armed autologous activated T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02607124",
            "title": "Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02626364",
            "title": "Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 705,
                    "therapyName": "Crenolanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02648633",
            "title": "Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4219,
                    "therapyName": "Nivolumab + Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02661282",
            "title": "Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9746,
                    "therapyName": "Autologous CMV-specific CTLs + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02743078",
            "title": "Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02798406",
            "title": "Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4408,
                    "therapyName": "DNX-2401 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02852655",
            "title": "A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",
            "phase": "Phase 0",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02871843",
            "title": "Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4596,
                    "therapyName": "RRx-001 + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02942264",
            "title": "TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5836,
                    "therapyName": "TG02",
                    "synonyms": null
                },
                {
                    "id": 5851,
                    "therapyName": "Temozolomide + TG02",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02977780",
            "title": "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1000,
                    "therapyName": "CC-115",
                    "synonyms": null
                },
                {
                    "id": 5028,
                    "therapyName": "Abemaciclib + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 5029,
                    "therapyName": "Neratinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03027388",
            "title": "Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3514,
                    "therapyName": "LB-100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03107780",
            "title": "MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1452,
                    "therapyName": "KRT-232",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03139916",
            "title": "Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5634,
                    "therapyName": "Bavituximab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03173950",
            "title": "Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03174197",
            "title": "Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5872,
                    "therapyName": "Atezolizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03197506",
            "title": "Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5221,
                    "therapyName": "Pembrolizumab + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277638",
            "title": "Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03344250",
            "title": "Phase I EGFR BATs in Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1012,
                    "therapyName": "EGFRBi-armed autologous activated T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03367715",
            "title": "Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03426891",
            "title": "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6703,
                    "therapyName": "Pembrolizumab + Temozolomide + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03452930",
            "title": "EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6104,
                    "therapyName": "Tinostamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03641326",
            "title": "Sunitinib in Sarcomas of the Central Nervous System",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03657576",
            "title": "Trial of C134 in Patients With Recurrent GBM (C134-HSV-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9748,
                    "therapyName": "C134-HSV-1",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03681028",
            "title": "Feasibility of Individualized Therapy for Recurrent GBM",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03707457",
            "title": "Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8138,
                    "therapyName": "MK-4166 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03856099",
            "title": "TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2515,
                    "therapyName": "Tanibirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03896568",
            "title": "Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4407,
                    "therapyName": "DNX-2401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03961971",
            "title": "Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8396,
                    "therapyName": "MBG453 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03970447",
            "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04013672",
            "title": "Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8566,
                    "therapyName": "Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04051606",
            "title": "Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04195139",
            "title": "Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3724,
                    "therapyName": "Nivolumab + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04216329",
            "title": "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9172,
                    "therapyName": "Selinexor + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04225039",
            "title": "Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9247,
                    "therapyName": "INCAGN01876 + INCMGA00012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04254419",
            "title": "Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                
            ]
        }
    ]
}